InterMune Cuts Staff | Chemical & Engineering News
Volume 85 Issue 13 | p. 26 | Concentrates
Issue Date: March 26, 2007

InterMune Cuts Staff

Department: Business

InterMune is cutting about 116 positions, or half its staff, following its halt earlier this month of a late-stage trial of Actimmune to treat idiopathic pulmonary fibrosis (IPF), a chronic lung disease. Actimmune, the firm's synthesized version of interferon , is approved to treat two rare diseases but was found ineffective in treating IPF. InterMune says it will refocus its resources on two other drugs in its pipeline: pirfenidone, a small-molecule drug in Phase III trials for treating IPF, and a hepatitis C virus protease inhibitor in Phase Ia trials.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment